MMP9 and prostate carcinoma: Inhibition of SENP1 expression in high-grade metastatic prostate cancer cells can affect the bone remodeling ability of HIF-1α and its downstream matrix metalloproteinase (MMP)-2 and MMP-9, and then inhibit the bone metastasis of prostate cancer cells (31).